Surendra Shenoy
Research Subjects
Surendra Shenoy has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey A. Lowell
Departments of Surgery
3 shared publications Todd K. Howard
Section of Transplantation, Washington University School of Medicine, St Louis, MO
3 shared publicationsWilliam Chapman
3 shared publicationsJeffrey A. Lowell
Department of Medicine, Washington University, St. Louis, MO
2 shared publicationsJeffrey Crippin
Department of Surgery, Washington University, St. Louis, MO
2 shared publicationsKaren L. Hardinger
Department of Pharmacy Practice, University of Missouri–Kansas City, Kansas City, MO
2 shared publications
Latest Publications
- 1 September 2016
- Published by Elsevier in Human Immunology
- Vol. 77, 79
P055 Development of immune responses to tissue-restricted self-antigens in simultaneous kidney-pancreas transplant recipients with acute rejection
- 1 September 2016
- Published by Elsevier in Human Immunology
- Vol. 77, 79
P055 Development of immune responses to tissue-restricted self-antigens in simultaneous kidney-pancreas transplant recipients with acute rejection
- 18 April 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (1) , 193-201
Results of Simultaneous Liver and Kidney Transplantation: A Single-Center Review
The decision for a simultaneous liver and kidney transplant (SLKT) is fraught with controversy. The aim of this study was to compare SLKT to liver transplant alone (LTA) in patients with pre-transplant renal failure.A retrospective review comparing patients undergoing SLKT and LTA (with renal failure) between January 2000 and December 2014 was performed.Of 1129 liver transplants, 132 had renal failure pre-transplant; 52 had SLKT and 80 recipients had LTA. MELD and BMI were lower in the SLKT group (p=0.001). SLKT patients had better overall survival at 1, and 5 years compared to LTA (92.3%, 81.6%, vs. 73.3%, 64.3 % respectively p<0.01). Graft survival was also superior in patients undergoing SLKT than LTA. Six out of 52 (11.5%) SLKT recipients had final positive cross match but only 1/52(1.9%) kidney graft was lost to rejection. In the SLKT group 9/52 (17.3%) required dialysis post transplant but only 2 remained on dialysis beyond 30 days. All patients in LTA group were on dialysis pre-transplant and significantly more patients (52/80(65%)) required dialysis post LTA (p=<0.0001) and 31/80 (38.8%) were dialysis dependent for more than 30 days or died on dialysis within 30 days. 2 LTA recipients were subsequently listed for kidney transplant.Patients with end stage liver disease (ESLD) on dialysis who undergo liver transplant have significantly better survival when SLKT is performed. In selected patients SLKT is an appropriate utilization of a scarce resource but better prognostic indicators for selection of patients are still needed.
- 18 April 2016
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 223 (1) , 193-201
Results of Simultaneous Liver and Kidney Transplantation: A Single-Center Review
The decision for a simultaneous liver and kidney transplant (SLKT) is fraught with controversy. The aim of this study was to compare SLKT to liver transplant alone (LTA) in patients with pre-transplant renal failure.A retrospective review comparing patients undergoing SLKT and LTA (with renal failure) between January 2000 and December 2014 was performed.Of 1129 liver transplants, 132 had renal failure pre-transplant; 52 had SLKT and 80 recipients had LTA. MELD and BMI were lower in the SLKT group (p=0.001). SLKT patients had better overall survival at 1, and 5 years compared to LTA (92.3%, 81.6%, vs. 73.3%, 64.3 % respectively p<0.01). Graft survival was also superior in patients undergoing SLKT than LTA. Six out of 52 (11.5%) SLKT recipients had final positive cross match but only 1/52(1.9%) kidney graft was lost to rejection. In the SLKT group 9/52 (17.3%) required dialysis post transplant but only 2 remained on dialysis beyond 30 days. All patients in LTA group were on dialysis pre-transplant and significantly more patients (52/80(65%)) required dialysis post LTA (p=<0.0001) and 31/80 (38.8%) were dialysis dependent for more than 30 days or died on dialysis within 30 days. 2 LTA recipients were subsequently listed for kidney transplant.Patients with end stage liver disease (ESLD) on dialysis who undergo liver transplant have significantly better survival when SLKT is performed. In selected patients SLKT is an appropriate utilization of a scarce resource but better prognostic indicators for selection of patients are still needed.
- 1 February 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (2) , 173-180
A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients
Two-hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)-based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of cyclosporine A (CsA) monitored by C2 levels versus FK monitored by trough levels in de novo liver transplant recipients. After informed consent, 60 de novo liver transplant recipients were randomized in a 1:1 fashion to receive either FK (trough, 6-10 ng/mL) or CsA (C2, 600-1200 ng/mL) and corticosteroids. The 2 groups were similar for gender, race, indication for liver disease, and age. At 1 year, patient survival was similar (93% for FK versus 90% for C2). One patient in the FK arm was retransplanted because of recurrent hepatitis C virus (HCV). Early acute rejection occurred in 27% of FK-treated patients and 23% of CsA-treated recipients [P = not significant (NS)]. Recurrent HCV occurred in 21% of FK-treated patients and 61% of CsA-treated patient (P = 0.04). The incidence of other infections, new onset diabetes mellitus, requirement for antihypertensives, and requirement for cholesterol medications were similar between the groups. Annual calcineurin inhibitor costs were lower in the C2 arm ($5432 ± 2091 for C2 versus $8291 ± 3948 for FK, P = 0.001). Annual pretransplant drug costs ($2292 ± 2331 for C2 versus $2831 ± 2358 for FK, P = NS) and 1-year posttransplant drug costs ($17,214 ± 16,600 for C2 versus $15,151 ± 11,699 for FK, P = NS) were similar. In conclusion, immunosuppression with CsA, monitored by C2 levels, is safe, effective, and economical in liver transplant recipients and provides immunosuppression at least equivalent to that of FK. Liver Transpl 14:173–180, 2008. © 2008 AASLD.
- 1 February 2008
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 14 (2) , 173-180
A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients
Two-hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)-based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of cyclosporine A (CsA) monitored by C2 levels versus FK monitored by trough levels in de novo liver transplant recipients. After informed consent, 60 de novo liver transplant recipients were randomized in a 1:1 fashion to receive either FK (trough, 6-10 ng/mL) or CsA (C2, 600-1200 ng/mL) and corticosteroids. The 2 groups were similar for gender, race, indication for liver disease, and age. At 1 year, patient survival was similar (93% for FK versus 90% for C2). One patient in the FK arm was retransplanted because of recurrent hepatitis C virus (HCV). Early acute rejection occurred in 27% of FK-treated patients and 23% of CsA-treated recipients [P = not significant (NS)]. Recurrent HCV occurred in 21% of FK-treated patients and 61% of CsA-treated patient (P = 0.04). The incidence of other infections, new onset diabetes mellitus, requirement for antihypertensives, and requirement for cholesterol medications were similar between the groups. Annual calcineurin inhibitor costs were lower in the C2 arm ($5432 ± 2091 for C2 versus $8291 ± 3948 for FK, P = 0.001). Annual pretransplant drug costs ($2292 ± 2331 for C2 versus $2831 ± 2358 for FK, P = NS) and 1-year posttransplant drug costs ($17,214 ± 16,600 for C2 versus $15,151 ± 11,699 for FK, P = NS) were similar. In conclusion, immunosuppression with CsA, monitored by C2 levels, is safe, effective, and economical in liver transplant recipients and provides immunosuppression at least equivalent to that of FK. Liver Transpl 14:173–180, 2008. © 2008 AASLD.
- 27 May 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (10) , 1389-1392
Sirolimus Conversion in Liver Transplant Recipients With Renal Dysfunction: A Prospective, Randomized, Single-Center Trial
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction. Forty patients with renal dysfunction (24-hr CrCl 40-80 mL/min) were randomized to be withdrawn from the calcineurin inhibitor (CNI) and receive sirolimus (SRL) or to continue CNI (control arm). Improvement in 24-hour CrCl was seen in the SRL arm at 3 months (75 mL/min SRL vs. 56 mL/min control, P=0.012), whereas at 12 months there was a trend toward improvement in the SRL arm (72 mL/min SRL vs. 58 mL/min control, P=0.09). Two patients, one in each arm, developed steroid-sensitive rejection. Side effects of SRL were limited and included hyperlipidemia requiring treatment (15%), pruritus (5%), and mouth sores (25%). In this trial, SRL-based immunosuppression was a safe alternative to CNI. Although early improvements were observed, withdrawing CNI and replacing it with SRL did not result in a statistically significant improvement in renal function at 12 months of follow-up.
- 27 May 2007
- Published by Wolters Kluwer Health in Transplantation
- Vol. 83 (10) , 1389-1392
Sirolimus Conversion in Liver Transplant Recipients With Renal Dysfunction: A Prospective, Randomized, Single-Center Trial
This pilot trial was designed to assess the safety and efficacy of SRL in liver transplant recipients with renal dysfunction. Forty patients with renal dysfunction (24-hr CrCl 40-80 mL/min) were randomized to be withdrawn from the calcineurin inhibitor (CNI) and receive sirolimus (SRL) or to continue CNI (control arm). Improvement in 24-hour CrCl was seen in the SRL arm at 3 months (75 mL/min SRL vs. 56 mL/min control, P=0.012), whereas at 12 months there was a trend toward improvement in the SRL arm (72 mL/min SRL vs. 58 mL/min control, P=0.09). Two patients, one in each arm, developed steroid-sensitive rejection. Side effects of SRL were limited and included hyperlipidemia requiring treatment (15%), pruritus (5%), and mouth sores (25%). In this trial, SRL-based immunosuppression was a safe alternative to CNI. Although early improvements were observed, withdrawing CNI and replacing it with SRL did not result in a statistically significant improvement in renal function at 12 months of follow-up.
- 1 September 2005
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 39 (5) , 437-443
Economic Impact of the Beneficial Effect of Changing Vascular Anastomotic Technique in Hemodialysis Access
There is an urgent and compelling need to reduce the morbidity and expense of maintaining hemodialysis vascular access patency. We previously reported the beneficial effects of altering anastomotic technique on vascular access patency from a multicenter clinical trial. Interrupted anastomoses created with nonpenetrating clips showed significant improvement in primary, assisted primary, and secondary patencies of native vein fistulae (AVF) and synthetic arteriovenous grafts (AVG). In the current report, we provide an analysis of the economic impact of these procedures. The economic analysis is based on a subgroup of patients who underwent access procedures as outpatients during years 1998–1999 at a university-affiliated hospital that contributed 23% of procedures described in the multicenter clinical trial. Hospital charges and payments received were determined for fistula placement and for commonly performed surgical and endovascular procedures (thrombectomy and angioplasty) that maintain patency. Financial comparisons were based on the hospital's average accumulative charges and actual payments calculated on a daily basis. Cost curves were generated by using charge and payment data. Financial information was extrapolated to the entire study population to estimate the cost savings for the larger group. Both charge and payment calculations indicated financial benefit with the use of clips. When financial estimates were extrapolated to reflect the national volume, clip usage projected significant savings of $20 million for AVF and $30.8 million for AVG for every 1,000 days of access patency. Replacing conventional sutures with clips can reduce the morbidity and cost associated with maintaining permanent hemodialysis vascular accesses. This beneficial effect may be due to the biologic advantages of interrupted, nonpenetrating vascular anastomoses.
- 1 September 2005
- Published by SAGE Publications in Vascular and Endovascular Surgery
- Vol. 39 (5) , 437-443
Economic Impact of the Beneficial Effect of Changing Vascular Anastomotic Technique in Hemodialysis Access
There is an urgent and compelling need to reduce the morbidity and expense of maintaining hemodialysis vascular access patency. We previously reported the beneficial effects of altering anastomotic technique on vascular access patency from a multicenter clinical trial. Interrupted anastomoses created with nonpenetrating clips showed significant improvement in primary, assisted primary, and secondary patencies of native vein fistulae (AVF) and synthetic arteriovenous grafts (AVG). In the current report, we provide an analysis of the economic impact of these procedures. The economic analysis is based on a subgroup of patients who underwent access procedures as outpatients during years 1998–1999 at a university-affiliated hospital that contributed 23% of procedures described in the multicenter clinical trial. Hospital charges and payments received were determined for fistula placement and for commonly performed surgical and endovascular procedures (thrombectomy and angioplasty) that maintain patency. Financial comparisons were based on the hospital's average accumulative charges and actual payments calculated on a daily basis. Cost curves were generated by using charge and payment data. Financial information was extrapolated to the entire study population to estimate the cost savings for the larger group. Both charge and payment calculations indicated financial benefit with the use of clips. When financial estimates were extrapolated to reflect the national volume, clip usage projected significant savings of $20 million for AVF and $30.8 million for AVG for every 1,000 days of access patency. Replacing conventional sutures with clips can reduce the morbidity and cost associated with maintaining permanent hemodialysis vascular accesses. This beneficial effect may be due to the biologic advantages of interrupted, nonpenetrating vascular anastomoses.
- 1 August 2003
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 38 (2) , 229-235
A multicenter study of permanent hemodialysis access patency: beneficial effect of clipped vascular anastomotic technique
- 1 August 2003
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 38 (2) , 229-235
A multicenter study of permanent hemodialysis access patency: beneficial effect of clipped vascular anastomotic technique
- Open Access
- 1 May 1999
- Published by Wiley in Liver Transplantation and Surgery
- Vol. 5 (3) , 200-203
Unusual presentations of nonmycotic hepatic artery pseudoaneurysms after liver transplantation
- 1 May 1999
- Published by Wiley in Liver Transplantation and Surgery
- Vol. 5 (3) , 200-203
Open AccessUnusual presentations of nonmycotic hepatic artery pseudoaneurysms after liver transplantation
- 1 October 1995
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 88, S45
DELAYED CLEARANCE OF HEPATITIS B SURFACE ANTIGEN (HBsAg) AFTER IMMUNOPROPHYLAXIS FOR LIVER TRANSPLANTATION
- 1 October 1995
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 88, S45
DELAYED CLEARANCE OF HEPATITIS B SURFACE ANTIGEN (HBsAg) AFTER IMMUNOPROPHYLAXIS FOR LIVER TRANSPLANTATION
- 1 March 1995
- Published by Wolters Kluwer Health in Transplantation
- Vol. 59 (5) , 794-795
LIVING UNRELATED RENAL TRANSPLANTATION FOR SICKLE CELL NEPHROPATHY
- 1 March 1995
- Published by Wolters Kluwer Health in Transplantation
- Vol. 59 (5) , 794-795
LIVING UNRELATED RENAL TRANSPLANTATION FOR SICKLE CELL NEPHROPATHY